Texas Heart Institute

Houston, TX, United States

Texas Heart Institute

Houston, TX, United States

The Texas Heart Institute is a not-for-profit cardiology and heart surgery center located within the Texas Medical Center in Houston, Texas. Founded in 1962 by Dr. Denton A. Cooley, its original charter stated its purpose was “the study and treatment of diseases of the heart and blood vessels. Today, the Institute’s mission is to reduce the devastating toll of cardiovascular disease through innovative programs in research, education, and improved patient care. The Texas Heart Institute and its clinical partner, St. Luke's Episcopal Hospital, have become one of the nation's largest cardiovascular centers. Its 160-member professional staff have performed more than 100,000 open heart operations, 200,000 cardiac catheterizations, and 1,000 heart transplants. In 2010, in its annual survey of “America's Best Hospitals,” U.S. News & World Report ranked the Texas Heart Institute at St. Luke's Episcopal Hospital number 4 in the United States for heart care, making this its 20th consecutive year as one of the top 10 heart centers in the country. Wikipedia.


Time filter

Source Type

Patent
Texas Heart Institute | Date: 2015-04-22

An effective amount of a composition comprising a stem cell, a stem cell engraftment enhancer, and a carrier fluid, for use in the treatment of an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease. A composition comprising PGI2-overexpressing human mesenchymal stem cells (PGI2-hMSCs), and a carrier fluid; wherein an effective amount of the composition is administered via a single treatment stream as an intramuscular injection to an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease, and wherein stem cell engraftment is enhanced in said individual by greater than about 200%, when compared to stem cell engraftment in an individual treated with a composition lacking the stem cell engraftment enhancer.


Patent
Texas Heart Institute | Date: 2015-04-22

An effective amount of a composition comprising (i) a plasmid having a cyclooxygenase-prostacyclin synthase fusion gene, and (ii) a carrier fluid for use in treating an individual having a vascular disease or at risk of developing a vascular disease. A composition comprising a carrier fluid; and a DNA sequence encoding for a triple catalytic enzyme, a cDNA sequence encoding for a triple catalytic enzyme, a plasmid comprising a DNA sequence encoding for a triple catalytic enzyme, a fusion gene encoding for a triple catalytic enzyme, a cyclooxygenase-prostacyclin synthase fusion gene, or combinations thereof, for use in treating an individual having a vascular disease or at risk of developing a vascular disease.


A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of 41, 51, 47, v3 and L2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.


Patent
Rice University, Baylor College of Medicine and Texas Heart Institute | Date: 2015-02-20

Systems and methods for deploying and securing conductive materials to a region of tissue may utilize a catheter. The catheter may provide a tip with one or more detachable sections or may provide an adjustable opening. A lumen of the catheter may provide a conductive material, such as a filament, fiber, network or patch of carbon nanotubes (CNTs) or carbon nanofibers (CNFs). In some embodiments, the conductive materials may be coupled to securing mechanisms, such as screws, clips, anchors, alligator clips, or anchors with barbs, which can be actuated to attach the conductive materials to desired regions of tissue. In some embodiments, the catheter may provide a needle tip that allows the conductive material to be embedded into desired regions of tissue by inserting the needle into the tissue.


Patent
Actuated Medical, Baylor College of Medicine and Texas Heart Institute | Date: 2016-09-16

A system, device and method for insertion of a penetrating member into tissue is disclosed, which may be handheld and automated. A detector obtains data regarding subdermal locations of tissue structures, including cavities such as blood vessels. A processor calculates the distance between a preselected target point below the tissue surface, such as within a blood vessel, and the tissue surface, and adjustment data for vertical, angular and extension adjustment of the penetrating member. Vertical, angular and extension actuators carry out the adjustments in real-time as calculated and directed by the processor. Changes in the location of the target point result in automatic recalculation and adjustment by the processor and various actuators. A vibrational actuator induces vibration to the penetrating member during insertion, overcome tissue deformation and vein rolling. A guidewire may be inserted through or by the device, for dilator and catheter insertion once the penetrating member is removed.


Patent
Texas Heart Institute | Date: 2017-03-01

An effective amount of a composition comprising a stem cell, a stem cell engraftment enhancer, and a carrier fluid, for use in the treatment of an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease. A composition comprising PGI2-overexpressing human mesenchymal stem cells (PGI2-hMSCs), and a carrier fluid; wherein an effective amount of the composition is administered via a single treatment stream as an intramuscular injection to an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease, and wherein stem cell engraftment is enhanced in said individual by greater than about 200%, when compared to stem cell engraftment in an individual treated with a composition lacking the stem cell engraftment enhancer.


Patent
Texas Heart Institute | Date: 2017-03-01

An effective amount of a composition comprising (i) a plasmid having a cyclooxygenase-prostacyclin synthase fusion gene, and (ii) a carrier fluid for use in treating an individual having a vascular disease or at risk of developing a vascular disease. A composition comprising a carrier fluid; and a DNA sequence encoding for a triple catalytic enzyme, a cDNA sequence encoding for a triple catalytic enzyme, a plasmid comprising a DNA sequence encoding for a triple catalytic enzyme, a fusion gene encoding for a triple catalytic enzyme, a cyclooxygenase-prostacyclin synthase fusion gene, or combinations thereof, for use in treating an individual having a vascular disease or at risk of developing a vascular disease.


Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which may be used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions. Compositions and methods including the mimetics enhance: (1) the priming of vaccines (including, but not limited to, cancer vaccines); (2) cytolytic activity of adoptive cell therapies (including, but not limited to T-cells, CTLs, NK, iNKT); (3) immunotherapies (including, but not limited to, negative checkpoint blockage strategies such as anti-CTLA-4 and anti-PD-1); and (4) biologic therapies (including, but not limited, to trastuzumab and rituxamab), whereby the mechanism-of-action includes antibody dependent cellular cytotoxicity (ADCC).


A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of 41, 51, 47, v3 and L2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.


A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of 41, 41, 47, 43 and L2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

Loading Texas Heart Institute collaborators
Loading Texas Heart Institute collaborators